DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)
Launched by ASTRAZENECA · Sep 8, 2008
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically confirmed metastatic tumour which is refractory to standard therapies
- • At least one lesion size ≥3cm on in longest diameter suitable for repeat assessment by DCE-CT and DCE-MRI
- • Patients must be able to undergo DCE-CT and DCE-MRI scanning procedures
- • Life expectancy of at least 12 weeks
- Exclusion Criteria:
- • Patients with hormone refractory prostate cancer (HRPC)
- • Patients with a history of poorly controlled high blood pressure
- • Ineligibility for MRI scanning or DCE-CT or DCE-MRI scanning
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Jane Robertson, MD
Study Director
AstraZeneca, Alderley Park
Johann De Bono, MD
Principal Investigator
Institute of Cancer Research, Royal Marsden Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials